Find Clinical Trials & Studies

Visit the Research & Education Institute

L-Annamycin for Injection With Cytarabine Injection As 2nd Line Therapy for Remission Induction

I'm Interested!

Please call
1-800-641-2422

A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination With Cytarabine Injection Versus Placebo in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed Acute Myeloid Leukemia

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Leukemia

Study Purpose

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

Principal Investigator
Benjamin Tomlinson MD

Department/Division
Cancer (Leukemia)

UH IRB: Pro00087506
StudyID: MOLE1925
ClinicalTrials.gov: NCT06788756

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422